APOL1

– ADPKD is the most common inherited kidney disease, with no treatments currently available that address the underlying cause of disease – – Vertex to initiate a Phase 1 clinical trial in healthy volunteers this month – – ADPKD is Vertex’s 10th disease area in the clinic, further expanding the company’s pipeline of potentially transformative medicines for serious diseases – BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants. ADPKD is the most common inherited kidney disease, with an estimated 250,000 people in the U.S. and Europe living with ADPKD; however, there are no treatments currently available that address the underlying causal biology of the disease. ADPKD is a life-shortening genetic kidney disease characterized by the growth of numerous kidney-enlarging cysts that impair kidney function and can ultimately lead to kidney failure, requiring dialysis or kidney transplantation, and premature death. The majority of ADPKD cases are caused by variants in the PKD1 gene, which encodes the polycystin 1 (PC1) protein. These inherited variants lead to a loss of PC1 function that results in cyst growth. VX-407 is a first-in-class small molecule corrector that is designed to target the underlying cause of ADPKD in a subset of patients with PKD1 variants, estimated at ~25,000 (or ~10%) of the overall ~250,000 ADPKD patient population, by restoring function to the variant PC1 protein. Vertex plans to initiate a Phase 1 clinical trial of VX-407 in healthy volunteers this month. “The advancement of VX-407, a first-in-class molecule for the treatment of ADPKD, into the clinic represents another important opportunity to transform the treatment of a serious disease,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “Just as our approach in cystic fibrosis allowed us to reach more patients over time, our goal here is to serially innovate to reach the 250,000 people suffering from ADPKD.” About Autosomal Dominant Polycystic Kidney Disease (ADPKD) ADPKD is the most common inherited kidney disease and one of the most common severe Mendelian genetic diseases, affecting approximately 250,000 diagnosed people in the U.S. and Europe. As an autosomal dominant disease, one affected parent can pass on the disease to their children. In most cases, ADPKD is caused by variants in the PKD1 and PKD2 genes, which express proteins known as polycystins. The majority of ADPKD patients (~80%) have a variant in the PKD1 gene, resulting in a loss of function of polycystin 1 (PC1). This leads to the proliferation of kidney epithelial cells, increased fluid secretion and the formation and expansion of numerous fluid-filled cysts. The progressive cyst formation causes an increase in kidney size and decline in kidney function. Around half of patients with ADPKD experience kidney failure by the age of 60. Kidney cysts can also lead to severe abdominal pain, cyst infection, blood in the urine and kidney stones, all of which significantly impair quality of life. About VX-407 VX-407 is a first-in-class small molecule corrector that is designed to treat ADPKD in patients with a subset of PKD1 variants, estimated at ~25,000 (or ~10%) of the overall ~250,000 ADPKD patient population, by correcting defective PC1 folding to restore function. In doing so, the aim is to stop growth of kidney cysts and reduce kidney volume, thereby preventing progression to kidney failure. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Carmen Bozic, M.D., in this press release, statements regarding plans to initiate a Phase 1 clinical trial of VX-407 in healthy volunteers this month, and estimates regarding the potential eligible patient population. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company’s research and development programs may not support registration or further development of its compounds due to safety, efficacy, and other risks listed under the heading “Risk Factors” in Vertex's annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company's website at and . You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN)

LONDON--( BUSINESS WIRE )-- Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KALYDECO ® (ivacaftor) for the treatment of infants with cystic fibrosis (CF) ages 1 month to less than 4 months old who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene: R117H , G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N or S549R . “ Cystic fibrosis is a chronic, progressive disease that is present from birth, which is why it is important to treat the underlying cause of this disease as early as possible to potentially slow disease progression,” said Fosca De Iorio, Vice President, International Medical Affairs at Vertex. “ If the label expansion for KALYDECO is approved, this would allow eligible infants with CF to receive a treatment that targets the underlying cause of their disease at the very start of their lives.” In the European Union, KALYDECO ® is already approved for the treatment of people with CF ages 4 months old and above with specific mutations in the CFTR gene. About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 92,000 people globally. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving. Diagnosis of CF is often made by genetic testing and is confirmed by testing sweat chloride (SwCl), which measures CFTR protein dysfunction. The diagnostic threshold for CF is SwCl ≥60 mmol/L, while levels between 30-59 indicate CF is possible and more testing may be needed to make the diagnosis of CF. A SwCl level of <30 mmol/L is seen in people who carry one copy of the CF gene but do not have any manifestation of disease (carriers). Higher levels of SwCl are associated with more severe disease. Restoring CFTR function leads to lower levels of SwCl. About KALYDECO ® (ivacaftor) In people with certain types of mutations in the CFTR gene, the CFTR protein at the cell surface does not function properly. Known as a CFTR potentiator, ivacaftor is an oral medicine designed to facilitate the ability of CFTR proteins to transport salt and water across the cell membrane, which helps hydrate and clear mucus from the airways. KALYDECO ® (ivacaftor) was the first medicine to treat the underlying cause of cystic fibrosis in people with specific mutations in the CFTR gene. KALYDECO ® (ivacaftor) is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged at least 4 months and older who have the following mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene: R117H , G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N or S549R . For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu . About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn , YouTube and Twitter/X . Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Fosca De Iorio, Vice President, International Medical Affairs at Vertex, in this press release, statements regarding the eligible patient population for KALYDECO, and statements regarding the potential benefits of KALYDECO. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company’s development programs may not support a label expansion for KALYDECO, that regulatory authorities in the E.U. may not approve a label expansion for KALYDECO on a timely basis or at all, and other risks listed under the heading “Risk Factors” in Vertex's annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com and www.sec.gov . You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN)

礼来与诺和诺德正朝着全球首个万亿市值药企冲击；挤进前20的医药一哥恒瑞，无疑给业界传递着回暖信号。过去一年，有人走到了聚光灯下，也有人消失在榜单，成为资本市场“宠儿”的密码究竟是什么？制药业的万亿市值药企，可能真的快来了。在阿尔茨海默病新药与GLP-1的双重加持之下，礼来在过去一年开启市值狂飙，一年内市值飙升140%，从首次突破4000亿美元大关到如今在7000亿美元一骑绝尘，礼来仅仅用了8个月的时间。胡润研究院发布的《2023胡润世界500强》中，礼来成为了全球最具价值的制药公司，也是榜单前十中唯一的一家制药企业。同样受当红炸子鸡“GLP-1”加持的诺和诺德也不甘示弱，一年内市值涨幅77%，轻松站上5000亿美元市值。在《2023胡润世界500强》的排名上升30位，至第14。正如世界上最大的主权投资基金挪威银行投资管理公司（NBIM）预测，诺和诺德或礼来可能成为第一家市值冲破1万亿美元大关的制药公司，与美国大型科技股七巨头并驾齐驱。礼来与诺和诺德的市值“狂欢”已经让昔日的市值之王强生望尘莫及。曾一度突破4000亿美元市值的强生，在过去一年市值下滑8%，停留在3770亿美元。即使从头把交椅滑落，强生的市值依然领先身后的默沙东500多亿美元。老牌MNC们，如艾伯维、默沙东、罗氏、阿斯利康、诺华，虽然市值有涨有跌，不过都稳定在2000亿-3000亿美元之间。而宇宙大药厂辉瑞受新冠“红利”将难以持续，业绩不及预期的影响，市值跌去35%，不足1600亿美元.若将目光放至全球上市药企市值Top20，值得注意的是，全球药企千亿市值俱乐部中，出现两家biopharma的身影，福泰制药与再生元。它们在过去一年都有着亮眼的表现。恒瑞也不负众望的成为TOP20中唯一的中国药企，来到第18位。但几家欢喜几家愁，TOP20中，过半数的药企都遭遇了或多或少的市值缩水。莫德纳以49%的降幅“领跌”。市值反映着药企实力以及未来预期的综合指标。企业当下的业绩表现、核心业务的未来预期、公司的经营管理等等都牵动着二级市场的神经。过去一年里，谁成为了投资者的宠儿，又有谁被“抛弃”？市值破万亿的MNC，能否不靠GLP-1？全球市值TOP20的制药企业中，有近1半的企业在过去1年有一定涨幅，其中涨势最好的药企，都有两大共同的刺激因素：一是超级大单品在快速放量，且还具备广阔的增长空间（有的被业内公认为是同领域史上最好的药物）；二是公司本身较高较稳的盈利能力，以及在优势领域有着较强的产品迭代和接续能力。正如恒瑞能成为进入全球制药企业市值TOP20的唯一一家中国药企，释放了明确的信号，恒瑞在过去一年中的人事变动、业务调整、BD交易受到了市场认可。也许就在今年，医药人能够见证史上首个进入万亿美元市值俱乐部的制药企业，最大的刺激因子是GLP-1。而如果没有GLP-1，没有礼来和诺和诺德，近3年股价增长态势最好的制药巨头，当属新“药王”的缔造者——默沙东。默沙东股价在3年内上涨约65%，5年内上涨约75%，2024年年初至今上涨了13%。2022年，默沙东股价实现了20多年来最佳年度涨幅，是当年标普500指数中表现最好的医药公司。有资深投资人预测，未来10年，默沙东的表现可能比标普500指数高出40%以上，在下一次经济衰退期间削减股息的风险仅为0.5%。这离不开默沙东近10年且高且稳的营业利润率。据统计，2018年到2023年，默沙东营业利润率几乎没有跌出过20%，2022年和2023年（35%）增长尤为明显。在2024年初的JPM大会上，默沙东表示将利用在肺癌等领域的强者优势，到2025年实现43%的营业利润率，此外其21价肺炎球菌疫苗V116和肺动脉高压产品sotatercept也都提供了想象空间。但超40%的利润率究竟怎么来？在专利悬崖到来之前的K药要拼，HPV疫苗也要拼。现在K药一年能大卖250亿美元，但司美格鲁肽紧跟其后。如果以单药或通过联用疗法成为多个肿瘤适应证的一线疗法，K药已经到了天花板级别，想要挖深护城河、搭高壁垒，业界公认“PD-1+ADC”是一款利器。也因此，默沙东近两年抛出近400亿美元围猎ADC，另外2023年狂砸研投，接下来还会在20多项III期临床研究上继续加大布局。当然，如今谈起市值，已然躲不过GLP-1，无法忽略礼来和诺和诺德。全球最大的主权财富基金——挪威国家银行投资管理公司预计，礼来和诺和诺德或将成为首批市值突破万亿美元的医疗保健股。1月底财报一出，诺和诺德市值一夜突破5000亿，华尔街分析师预计，诺和诺德未来5年的营收复合年增长率约为23%。值得注意的是，诺和诺德的成功，不能仅归因于司美格鲁肽减肥适应证获批后的造福神话。翻看其近10年来的财报会发现，这家专注于“聚焦”路线的成长型MNC，盈利能力一直都较强。有数据统计，过去10年，诺和诺德的息税前利润率高达40%，高于礼来、辉瑞、艾伯维、BMS等MNC。只要解决掉产能供不应求这个最大的问题，GLP-1足以让诺和诺德持续享受高光。就在诺和诺德市值破5000亿前后，礼来市值突破了6000亿，又在13天后火速冲破7000亿美元门槛，静态市盈率高达120倍。仅1年的时间，礼来市值翻了1倍之多，领先于特斯拉，目前在标普500指数中仅次于微软和苹果。2023年，礼来全球总营收增幅为20%，主要得益于替尔泊肽两款产品（Mounjaro和Zepbound）的放量。其中，替尔泊肽降糖版Mounjaro销售额突破50亿美元，同比大增970%；减重版Zepbound上市不到两个月收入已接近2亿美元。当然，作为GLP-1“双王”，礼来和诺和诺德彼此之间的竞争也是异常激烈，礼来近期再度展开了一项三靶点激动剂与司美格鲁肽的III期头对头试验，用于二甲双胍联合或不联合SGLT2i抑制剂治疗血糖控制不佳的2型糖尿病患者治疗。市值破千亿的Biopharma：底层技术的胜利与去年同期相比，新增两家市值破千亿美元的制药公司：截至发稿日收盘，再生元制药市值达到1040.6亿美元，增长200亿美元；福泰制药市值达1090.58亿美元，增长300亿美元。而这两家公司虽然增长原因各异，但共同的特点是都构建了完备的底层技术基础，并在2023年的营收上得到了验证。根据两家公司的财报，再生元2023年全年营收131.17亿美元，同比增长近8%；2023年，福泰制药的收入已经达到98.69亿美元，同比增长11%。由于强劲的产品销售增长，后者的现金流更是高达137亿美元，较上年同期增长近30亿美元。再生元制药的融合蛋白技术和抗体工程技术平台在业界鼎鼎大名，诞生了阿柏西普和度普利尤单抗两大重磅产品。如果说此前再生元凭借核心技术平台诞生了多款重磅抗体药物，那么现如今，再生元的发展已经呈现出对于新技术整合发力的趋势。从发展路径上可以看到早在2014年再生元就建立了“再生元遗传学中心（RGC）”，从人类遗传基因测序领域寻找新药开发机会，此后又通过合作和收购的形式布局了基因疗法、RNAi疗法、T细胞疗法等多种前沿赛道。进入2023年后，再生元对新技术的整合趋势更加明显：8月，再生元宣布以1.09亿美元收购基因治疗公司Decibel Therapeutic，该公司的C5补体抑制剂Veopoz也同期获得FDA批准上市；2024年1月，再生元再次出手收购细胞疗法公司2seventy bio，并基于此成立新的细胞疗法部。有意思的是，这两家公司都曾是再生元的合作伙伴。福泰制药的成功则得益于在罕见病领域的聚焦和不断加固的基因药物技术。自2001年发掘罕见病囊性纤维化这一潜力极大的领域，此后对该领域产品进行了数次迭代，成为了囊性纤维化领域统治级地位的公司，4款获批治疗囊性纤维化的药物Kalydeco、Orkabi、Symdeko和Trikafta几乎“无死角”击溃囊性纤维化。其中，三代囊性纤维化组合疗法TRIKAFTA/KAFTRIO全年销售额89.45亿美元，同比增长16%，冲击百亿美金重磅炸弹。在开发过程囊性纤维化产品的过程中，福泰制药也积累了坚实的基因药物开发相关的技术，和多款罕见病用药产品。2023年底，福泰制药与“CRISPR技术三巨头”之一CRISPR Therapeutics合作的基因编辑疗法Casgevy成为全球首个获批的基因编辑疗法，并接连在英美获批上市。Casgevy就是福泰制药在基因疗法领域实力的成果之一。另一方面，在多年深耕囊性纤维化领域的过程中，福泰也创造了多款明星产品。在2023年12月，重磅新型镇痛药VX-548二期临床试验成功，消息发布当日，福泰制药的股价飞升13%，成为其跨入市值千亿美元俱乐部的“临门一脚”。据悉，VX-548是全球进展最快的Nav1.8抑制剂，曾被FDA 授予突破性疗法认定。此外，福泰制药还布局了疼痛、镰状细胞病、β-地中海贫血、α-1 抗胰蛋白酶缺乏症、APOL1 介导的肾病、杜氏肌营养不良症、1 型糖尿病等多个有望产出“大爆”单品的领域。近一半MNC市值下降背后的落寞在礼来、诺和诺德引发市值狂欢后，却仍难掩更多药企的一片跌声。纵观所有在榜药企，不同于礼来、诺和诺德市值一度疯狂上涨，也不同于福泰制药、再生元凭借稳扎稳打的技术平台及管线一路稳步前行，这些全球药企市值TOP20药企中，超一半市值或多或少有所下降，引人唏嘘，排名遍布各个阶段。而背后原因无外乎几大方面。一是部分药企仍在消化“新冠后遗症”，典型的如辉瑞、莫德纳。新冠疫情的逐渐消散，直接给了依靠新冠产品“致富”的药企一锤重击。莫德纳的起起伏伏便诠释了这一局面的无奈。回头看，2020年初，莫德纳市值还仅约70亿美元左右；但在一场新冠疫情后，便成为华尔街资本极力追捧的对象之一，市值一度破千亿，甚至还曾超过部分老牌药企巨头，当然伴随而来的还有不少诟病，如股价涨幅是否名副其实。答案或许显而易见。尤其是随着后疫情时代来临，新冠产品需求大幅下降，莫德纳的“造富神话”亦大打折扣，股价也开始急转直下，甚至在过去一年以49%的降幅在所有在榜药企中“领跌”。整体上也不如过往“活跃”，几近“销声匿迹”，偶尔更新的新动态也没能完全挽回诸多投资者的信心，从而市值在这一年内有如此表现尚在意料之内。而宇宙大药厂辉瑞与莫德纳有些“同病相怜”。旗下新冠药物Comirnaty和Paxlovid销售大幅缩减影响不容小觑。根据最新更新的财报，2023年因新冠疫苗Comirnaty和口服药物Paxlovid收入的大幅下降，辉瑞全年总营收下降至584.96亿美元，暴跌近41%。这与2023年年初的辉煌已然截然不同。彼时，辉瑞打破过往记录，成为全球首个年收入超千亿美元的制药企业，一时风光无两。不过，隐忧也早已浮现，摆在辉瑞2023年面前的拷问贯穿始终，除了新冠产品，后续哪款产品能为辉瑞延续辉煌？为应对2023年业绩可能产生的巨大滑坡，辉瑞会采取哪些措施？为了应对业绩必然下滑的结局，辉瑞在过去的一年也采取了不少措施，试图找寻一下个重磅产品，如在2023年加码布局ADC（抗体偶联药物）领域，以430亿美元收购ADC领域药企Seagen。另一方面，辉瑞也进行了成本调整计划，预计到2024年底，每年净成本节省至少40亿美元。二是专利悬崖困扰已久，BMS、罗氏、强生等诸多上榜药企都是其中的“困兽”。从稳居市值第一到而今，强生多少有些落寞。礼来和诺和诺德市值的势如破竹一路冲至前方，强生只能退居其后，市值也跌出4000多亿元。而今同样面临着较大的专利悬崖，如明星产品Stelara。在各项评估中，强生也开始显现“劣势”，先是跌出了《制药经理人》杂志（PharmExec）公布的2023年全球制药企业TOP50榜单前五，后又在前不久公布的《2023胡润世界500强》中价值下滑。BMS则跌得不相上下，下滑超400亿美元市值，也一路跌出前10。专利悬崖也始终困扰着BMS，除了蝉联多年小分子销售冠军的血液肿瘤药来那度胺自2022年仿制药进入美国市场后，销售额呈断崖式下跌外，还有更多的产品面临同样困局。翻开产品管线，如泊马度胺和达沙替尼2023年销售额已出现下滑态势；Opdivo、阿巴西普等产品则呈个位数增长。再看罗氏，在多年来常为人所称道的“三架马车”中，它押注了不少产品在肿瘤领域，但同样遭遇专利悬崖挑战已久，如曲妥珠单抗、贝伐单抗和利妥昔单抗便因专利悬崖而销售额大幅下跌。抛开上述药企外，阿斯利康、吉利德科学、武田制药等跨国药企市值均有所下降，不过总体来说，并不如那么“明显”。而发生在上述药企身上的故事，传导至资本市场，一幕幕都直接作用在了股价和市值表现上。精彩推荐CM10 | 集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化 ｜ 猎药人系列专题 | 出海启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖 ｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 |  荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药 ｜再鼎医药｜亚虹医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元